OQROGet OQRO Pro
Insider trade

Gilead Sciences (GILD)CEO sold ~$808K

Daniel Patrick O'day, CEO at Gilead Sciences, sold ~$808K of Gilead Sciences shares.

~$808K
Approx. value · 5,408 sh @ $149.38
577K
Holds after · shares reported
Traded
Sep 1, 2026
Filed
Sep 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  2. Jul 15, 2026Insider · 2 peopleInsiders: 2 sales (~$780K)
  3. Aug 3, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
  4. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  5. Aug 17, 2026Insider · 2 peopleInsiders: 3 sales (~$4.3M)
  6. Aug 20, 2026Insider · 1 personInsiders: 5 sales (~$725K)
  7. Aug 26, 2026Insider · 1 personInsiders: 4 sales (~$2.7M)
  8. Aug 27, 2026FDAFDA drug approval: Bixlenvo Sunlenca Starter Pack (Copackaged)
  9. Aug 27, 2026FDAFDA drug approval: Sunlenca
  10. Aug 27, 2026FDAFDA drug approval: Bixlenvo
  11. Aug 27, 2026FDAFDA drug approval: Sunlenca
  12. Sep 1, 2026 · this disclosureInsiderCEO sold ~$808K of GILD shares in the open market

What came next

  1. Sep 1, 2026Insider · 1 personInsiders: 2 sales (~$1.4M)
  2. Sep 15, 2026Insider · 2 peopleInsiders: 4 sales (~$869K)
  3. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$2.2M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 28 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 78 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Daniel Patrick O'day, Chairman & CEO

The full history of Daniel Patrick O'day, Chairman & CEO is on the profile page.

How this filing works

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data